We recently published results of an intact parathyroid hormone (PTH) assay using the INCSTAR N-tact PTH kit giving details of precision and assay performance'. We now compare the results with those of a two-site immunoradiometric (IRMA) assay for intact PTH which uses an antibody specific for PTH 38-84 bound to polystyrene beads and a labelled antibody specific for PTH 1-34. This method which is technically simpler is considered to have a determinant capability as good or better than the N-tact assay in the differential diagnosis of hypercalcaemia.
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Materials and methods
IRMA intact PTH kits were obtained from INCSTAR Corporation (Stillwater, Minnesota, USA). Assays were carried out on plasma using the N-tact method! and after storage at -20°C using the IRMA assay. SUBJECTS Specimens were taken from amongst the previously reported series1in groups as follows: 23 normals; 21 patients with surgically proven hyperparathyroidism; 13 patients with hypercalcaemia due to malignancy; and II patients with chronic renal failure. (0'38, 0·27); and for the chronic renal failure group 2'91, (1·89, 0'09).
Results
Using the IRMA assay the normal group had a mean (SD) PTH concentration of3·5 (1'46) pmol/L, giving a normal range of < 1'5-6,42 pmol/L, The lowest standard was 1·5 pmol/L and this was taken as the lower limit of detectability although values did appear to be measurable below this figure.
Between-assay coefficient of variation was 1·8% at a mean PTH level of 20·3 pmol/L and 6·8% at a mean level of 3·4 pmol/L.
Discussion
The IRMA assay uses 200 J.lL of plasma as opposed to 2·5 mL in the N-tact assay. The normal range obtained was very similar to that previously obtained with the N-tact kit (1'5-6'1)1 and was noted to be similar to ranges obtained by other methods for the estimation of intact PTH3.
The overall correlation between the two meth-ods was such that all patients remained within the same disease group for each assay result. The IRMA results in the hyperparathyroid group were shown to be significantly higher (P<O·OI) . This may be due to degradation of concentrated PTH in acid extracts following the separation process in the N-tact method.
In the malignant and in the chronic renal failure patients results showed good agreement, there was no significant discrepancy in any single pair of specimens.
It is considered that the IRMA PTH assay provides results that are essentially similar to those obtained with the N-tact assay, but with improved precision and technical superiority. The fact that the method gave significantly higher values in hyperparathyroidism may serve well in Comparison of PTH assays 377 increasing the discriminatory power of the test when used in the differential diagnosis of hypercalcaemia.
